NO20053046L - 4-okso-1(3-substituerte fenyl-1,4-dihydro-1,8-naftyridin-3-karboksamidfosfodiesterase-4-inhibitorer. - Google Patents

4-okso-1(3-substituerte fenyl-1,4-dihydro-1,8-naftyridin-3-karboksamidfosfodiesterase-4-inhibitorer.

Info

Publication number
NO20053046L
NO20053046L NO20053046A NO20053046A NO20053046L NO 20053046 L NO20053046 L NO 20053046L NO 20053046 A NO20053046 A NO 20053046A NO 20053046 A NO20053046 A NO 20053046A NO 20053046 L NO20053046 L NO 20053046L
Authority
NO
Norway
Prior art keywords
inhibitors
naphthyridine
dihydro
oxo
substituted phenyl
Prior art date
Application number
NO20053046A
Other languages
English (en)
Other versions
NO20053046D0 (no
Inventor
Daniel Dube
Michel Gallant
Yves Girard
Patrick Lacombe
Dwight Macdonald
Renee Aspiotis
Laurence Dube
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of NO20053046D0 publication Critical patent/NO20053046D0/no
Publication of NO20053046L publication Critical patent/NO20053046L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Forbindelser representert ved formel (I) (D eller et farmasøytisk akseptabelt salt derav, er fosfodiesterase-4-inhibi- torer anvendbare ved behandling av astma og inflammasjon og anvendbare for å øke kognisjon.
NO20053046A 2002-11-22 2005-06-21 4-okso-1(3-substituerte fenyl-1,4-dihydro-1,8-naftyridin-3-karboksamidfosfodiesterase-4-inhibitorer. NO20053046L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42861102P 2002-11-22 2002-11-22
PCT/CA2003/001800 WO2004048374A1 (en) 2002-11-22 2003-11-19 4-oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors

Publications (2)

Publication Number Publication Date
NO20053046D0 NO20053046D0 (no) 2005-06-21
NO20053046L true NO20053046L (no) 2005-07-27

Family

ID=32393431

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053046A NO20053046L (no) 2002-11-22 2005-06-21 4-okso-1(3-substituerte fenyl-1,4-dihydro-1,8-naftyridin-3-karboksamidfosfodiesterase-4-inhibitorer.

Country Status (23)

Country Link
US (2) US7342024B2 (no)
EP (1) EP1565464B1 (no)
JP (1) JP4499571B2 (no)
KR (1) KR20050085112A (no)
CN (1) CN100475813C (no)
AT (1) ATE402175T1 (no)
AU (1) AU2003283167B2 (no)
BR (1) BR0316458A (no)
CA (1) CA2506648C (no)
CL (1) CL2004001050A1 (no)
DE (1) DE60322417D1 (no)
EC (1) ECSP055809A (no)
HR (1) HRP20050451A2 (no)
IS (1) IS7839A (no)
MA (1) MA27566A1 (no)
MX (1) MXPA05005413A (no)
NO (1) NO20053046L (no)
NZ (1) NZ539812A (no)
PL (1) PL377237A1 (no)
RU (1) RU2312865C2 (no)
UA (1) UA82208C2 (no)
WO (1) WO2004048374A1 (no)
ZA (1) ZA200503586B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
IS7839A (is) * 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
US20090105479A1 (en) * 2005-10-27 2009-04-23 Merck & Co., Inc. 4-Oxo-1-3-Substituted Phenyl-1,4-Dihydro-1,8-Napthyridene-3-Carboxamide Phosphodiesterase-4 Inhibitor and a Method of Preparing Same
AR057555A1 (es) * 2005-10-27 2007-12-05 Merck Frosst Canada Ltd Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
EP2359826B1 (en) 2006-07-05 2013-10-30 Takeda GmbH Combination of HMG-COA reductase inhibitor rosuvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-N-oxide for the treatment of inflammatory pulmonary diseases
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
JP5373613B2 (ja) 2006-10-16 2013-12-18 バイオノミクス リミテッド 新規な抗不安薬化合物
DK2124944T3 (da) * 2007-03-14 2012-04-23 Ranbaxy Lab Ltd Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
TW200902025A (en) * 2007-04-11 2009-01-16 Alcon Res Ltd Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
EP2297106B1 (en) 2008-05-27 2014-07-16 AstraZeneca AB Phenoxypyridinylamide derivatives and their use in the treatment of pde4 mediated disease states
US20110082145A1 (en) * 2009-10-01 2011-04-07 Alcon Research, Ltd. Olopatadine compositions and uses thereof
WO2012003436A1 (en) * 2010-07-01 2012-01-05 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
CA2828780A1 (en) 2011-03-02 2012-09-07 Bionomics Limited Novel small-molecules as therapeutics
EP2707367B1 (en) 2011-05-12 2019-10-09 Bionomics Limited Methods for preparing naphthyridines
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2013187727A1 (en) * 2012-06-15 2013-12-19 Bio-Pharm Solutions Co., Ltd. Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
CN106316824B (zh) * 2016-08-18 2018-10-19 广州康瑞泰药业有限公司 一种合成2-氟环丙烷甲酸的新方法
EP3556758B1 (en) * 2016-12-16 2024-07-17 Cstone Pharmaceuticals (Suzhou) Co., Ltd. 1,2-dihydro-1,6-naphthyridin-2-one derivatives as cdk4/6 inhibitors
NZ777336A (en) 2018-12-28 2026-02-27 Regeneron Pharma Treatment of respiratory disorders with arachidonate 15-lipoxygenase (alox15) inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2808070A1 (de) 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
US5328908A (en) 1988-10-24 1994-07-12 Procter & Gamble Pharmaceuticals, Inc. Antimicrobial quinolone thioureas
US5321029A (en) * 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines
KR970705562A (ko) 1994-08-29 1997-10-09 오노다 마사요시 신규한 나프티리딘 유도체 및 이의 의약 조성물(Novel naphthyridine derivatives and medicinal composition thereof)
DE69631423T2 (de) 1995-08-02 2004-12-02 Darwin Discovery Ltd., Slough Chinolone und deren therapeutische verwendung
ES2169811T3 (es) * 1995-09-22 2002-07-16 Wakunaga Pharma Co Ltd Nuevos derivados del acido piridonacarboxilico o sus sales y agente antibacteriano que comprende el mismo como ingrediente activo.
US6297248B1 (en) 1997-04-06 2001-10-02 Suntory Limited 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor
JPH11106385A (ja) * 1997-08-06 1999-04-20 Suntory Ltd Ｉｖ型ホスホジエステラーゼ阻害作用を有する１−アリール−１，８−ナフチリジン−４−オン誘導体
DK1075477T3 (da) * 1998-05-05 2003-06-30 Altana Pharma Ag Nye benzonaphthyridin-N-oxider
AR029185A1 (es) * 1999-10-25 2003-06-18 Yamanouchi Pharma Co Ltd Derivado de naftiridina
US6794447B1 (en) * 2000-07-28 2004-09-21 Taylor Made Golf Co., Inc. Golf balls incorporating nanocomposite materials
JP4460221B2 (ja) * 2001-05-24 2010-05-12 メルク フロスト カナダ リミテツド １−ビアリール−１，８−ナフチリジン−４−オン系ホスホジエステラーゼ−４阻害薬
KR100824233B1 (ko) * 2001-10-10 2008-04-24 씨제이제일제당 (주) 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난3,4-디하이드로-1ｈ-나프탈렌 유도체
IS7839A (is) * 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar

Also Published As

Publication number Publication date
NO20053046D0 (no) 2005-06-21
IS7839A (is) 2004-05-23
UA82208C2 (en) 2008-03-25
ATE402175T1 (de) 2008-08-15
ECSP055809A (es) 2005-08-11
AU2003283167B2 (en) 2009-01-08
KR20050085112A (ko) 2005-08-29
NZ539812A (en) 2007-12-21
CA2506648C (en) 2011-01-25
US20050107402A1 (en) 2005-05-19
JP4499571B2 (ja) 2010-07-07
PL377237A1 (pl) 2006-01-23
HRP20050451A2 (en) 2006-02-28
AU2003283167A1 (en) 2004-06-18
CN100475813C (zh) 2009-04-08
ZA200503586B (en) 2006-07-26
MA27566A1 (fr) 2005-10-03
EP1565464A1 (en) 2005-08-24
EP1565464B1 (en) 2008-07-23
US20060058316A1 (en) 2006-03-16
JP2006508989A (ja) 2006-03-16
WO2004048374A1 (en) 2004-06-10
MXPA05005413A (es) 2005-08-03
DE60322417D1 (en) 2008-09-04
CL2004001050A1 (es) 2005-03-28
CA2506648A1 (en) 2004-06-10
US7342024B2 (en) 2008-03-11
BR0316458A (pt) 2005-10-11
RU2312865C2 (ru) 2007-12-20
RU2005119644A (ru) 2006-01-20
US7238706B2 (en) 2007-07-03
CN1738819A (zh) 2006-02-22

Similar Documents

Publication Publication Date Title
NO20053046L (no) 4-okso-1(3-substituerte fenyl-1,4-dihydro-1,8-naftyridin-3-karboksamidfosfodiesterase-4-inhibitorer.
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
AU2002246728A1 (en) Carboline derivatives
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
WO2003013484A3 (en) N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
TW200519111A (en) N3-substituted imidazopyridine C-KIT inhibitors
AU2002249890A1 (en) Carboline derivatives
AU2002213421A1 (en) Condensed pyridoindole derivatives
GEP20094638B (en) Benzimidazolone carboxylic acid derivatives
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
MXPA03010761A (es) Combinaciones farmaceuticas.
TW200508199A (en) Novel compound
AU2002213419A1 (en) Condensed pyridoindole derivatives
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
AU2001261707A1 (en) Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
AU2003258630A1 (en) Pyrimidine derivatives as selective cox-2 inhibitors
GB0319037D0 (en) 7-Azaindole Derivatives
CA2423357A1 (en) Fused heterocyclic derivatives as phosphodiesterase inhibitors
MY138681A (en) 4-oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors
UA86040C2 (ru) Производные индола, которые имеют активность антагонистов рецептора crth2
WO2003039231A3 (en) Compounds and methods for treating transplant rejection
IS8034A (is) Imídasó[4,5-B]kínólínafleiður og notkun þeirra sem NO-myndunarhemla

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application